Posters

Treatment of pseudophakic cystoid macular edema after uncomplicated cataract surgery with nepafenac

Poster Details

First Author: T.Topalidis GREECE

Co Author(s):    T. Vachtsevanos   E. Karakosta   L. Kazantzidis   D. Tsakpinis   E. Kaldi  

Abstract Details

Purpose:

Cystoid macular edema (CME) following cataract surgery has been recognized for over 50 years as one of the most common causes of poor visual outcome following cataract surgery. The incidence of CME is likely in the range of 1-2% using modern cataract extraction techniques. We report 2 cases of resolution of post-operative CME related to Irvine-Gass syndrome, treated with nepafenac after uneventful cataract surgery.

Setting:

Ophthalmology clinic, «O Agios Dimitrios» General Hospital of Thessaloniki

Methods:

Two patients wich presented with reduced vision 7 days after uncomplicated cataract surgery were enrolled in this study. Both patients underwent a complete ophthalmological examination included best-corrected visual acuity (BCVA), fundus examination, optical coherence tomography (OCT), and fundus fluorescein angiography (FFA) which showed CME. The patients were treated with nepafenac (1mg/ml) drops three times a day and were evaluated again in 1 month and 3 months.

Results:

In the first case the initial BCVA was 0.7 LogMAR. After 1 month treatment with nepafenac, CME regressed and BCVA improved to 0.2 LogMAR. CMT measured with OCT was 392 μm at baseline and decreased to 232 μm at the 3 month follow up. In the second case the initial BCVA was 0.45 LogMAR and improved to 0.3 LogMAR after 1 month treatment with nepafenac and 0.1LogMAR after 3 months and remained unchanged at the 6 month follow up. CMT measured with OCT was 398 μm at baseline and decreased to 229 μm at the final follow-up.

Conclusions:

Irvine-Gass syndrome remains a common cause of poor visual outcome after cataract surgery. The significant improvement observed in these 2 cases of postsurgical macular edema showed that nepafenac produced a sustained improvement in functional and anatomical outcome. FINANCIAL DISCLOUSRE: NONE